Neuronal Biomarkers in Predicting Neurodevelopmental Outcome in Term Babies with Perinatal Asphyxia

Catherine, R Christina; Bhat, B. Vishnu; Adhisivam, B; Bharadwaj, Shruthi K.; Vinayagam, Vickneshwaran; Chinnakali, Palanivel

doi:10.1007/s12098-020-03283-2

Cited by 16 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors reported improved motor development in children submitted to hypothermia compared with children in the normothermia group at 18 months of life, corroborating our results. These results may explain the positive outcomes of development in our study since both newborns improved their behaviors throughout the assessments (14). The authors reported improved motor development in children submitted to hypothermia compared with children in the normothermia group at 18 months old, corroborating our results (14).…”

Section: -34°c 33°csupporting

confidence: 89%

Therapeutic hypothermia as a neuroprotective strategy in newborns with perinatal asphyxia—case report

Oliveira

Teixeira

Fernandes

et al. 2023

Front. Rehabil. Sci.

View full text Add to dashboard Cite

BackgroundPerinatal asphyxia is a public health problem and the third major cause of death among children under 5 years.ObjectiveTwo clinical cases of newborns with perinatal asphyxia submitted to therapeutic hypothermia and the follow-up of their motor development after hospital discharge have been reported.MethodsThis retrospective case report study included two newborns with hypoxic-ischemic encephalopathy due to perinatal asphyxia who received a hypothermia protocol at the neonatal intensive care unit (NICU). The two newborns and their families were followed up at the outpatient clinic and assessed using the Hammersmith Child Neurological Examination, Alberta Child Motor Scale, and Denver Developmental Screening Test-II.ResultsThe newborns were submitted to a 72-hour hypothermia protocol. One newborn remained for 13 days in the NICU, while the other remained for 22 days. According to the multidisciplinary team, both cases presented with typical motor development with no cerebral palsy during the follow-up.ConclusionBoth cases showed positive results and a good prognostic for motor development. Therapeutic hypothermia may be a strategy to prevent neurologic sequelae in newborns with perinatal asphyxia, including cerebral palsy.

show abstract

Section: -34°c 33°csupporting

confidence: 89%

Therapeutic hypothermia as a neuroprotective strategy in newborns with perinatal asphyxia—case report

Oliveira

Teixeira

Fernandes

et al. 2023

Front. Rehabil. Sci.

View full text Add to dashboard Cite

show abstract

“…Catherine et al [24] evaluated whether serum levels of neuronal biomarkers correlated to neurodevelopmental outcomes in term neonates at 18 months who hypoxic ischemic encephalopathy and therapeutic hypothermia. They showed that serum neuronal biomarkers, S100B, and NSE levels were not correlated to long-term neurodevelopmental outcomes in that population.…”

Section: Discussionmentioning

confidence: 99%

The contribution of postnatal steroid administration to early brain damage in preterm babies with bronchopulmonary dysplasia

et al. 2021

View full text Add to dashboard Cite

The contribution of postnatal steroid administration to early brain damage in preterm babies with bronchopulmonary dysplasia ABSTRACT Background/aim: Postnatal corticosteroids are commonly used to treat bronchopulmonary dysplasia (BPD). We aimed to show whether S100 calcium-binding B (S100B), neuron-specific enolase (NSE), Tau protein or microtubule-associated protein tau (MAPT), and glial fibrillary acid protein (GFAP) levels would provide any evidence of early neurological damage in premature infants receiving postnatal low dose dexamethasone therapy for BPD treatment. Materials and methods:In this cohort study, 136 preterm infants diagnosed with BPD at ≤32 weeks of gestation formed the study group and 64 preterm infants formed the control group. NSE, S100B, GFAP, and MAPT levels were first measured before the postnatal corticosteroid treatment in both the patient and the control group on the 28th day and, for a second time, after treatment termination in the patient group.Results: There were significant differences between the measured GFAP, MAPT, and NSE values of the BPD and control groups on the 28th day, whereas there was no significant difference between the measured S100B values of the two groups. There were a statistically significant difference between the NSE values measured on the 28th day and after the treatment within the BPD group, whereas no significant difference existed between the GFAP, MAPT, and S100B values. Conclusion:NSE levels, which indicate brain damage in the early period, increased in preterm babies with BPD who had been administered postnatal dexamethasone.

show abstract

“…The largest of these was a clinical trial from China involving 194 neonates [ 55 ], but this trial has been heavily criticized for protocol violations, post-randomisation exclusion and poor follow-up rates. Six of these cooling trials were from the same hospital, but with mortality in the usual care arm varying between 7 % and 50 %, raising concerns about data credibility and duplicate publications [ [56] , [57] , [58] , [59] , [60] , [61] ]. Hence, although the pooled data from these trials show a reduction in mortality with cooling, such a meta-analysis has no scientific value [ 62 , 63 ] ( Fig.…”

Section: Introductionmentioning

confidence: 99%

Need for more evidence in the prevention and management of perinatal asphyxia and neonatal encephalopathy in low and middle-income countries: A call for action

Krishnan

Kumar

Variane³

et al. 2021

Seminars in Fetal and Neonatal Medicine

View full text Add to dashboard Cite

Although low- and middle-income countries (LMICs) shoulder 90 % of the neonatal encephalopathy (NE) burden, there is very little evidence base for prevention or management of this condition in these settings. A variety of antenatal factors including socio-economic deprivation, undernutrition and sub optimal antenatal and intrapartum care increase the risk of NE, although little is known about the underlying mechanisms. Implementing interventions based on the evidence from high-income countries to LMICs, may cause more harm than benefit as shown by the increased mortality and lack of neuroprotection with cooling therapy in the hypothermia for moderate or severe NE in low and middle-income countries (HELIX) trial. Pooled data from pilot trials suggest that erythropoietin monotherapy reduces death and disability in LMICs, but this needs further evaluation in clinical trials. Careful attention to supportive care, including avoiding hyperoxia, hypocarbia, hypoglycemia, and hyperthermia, are likely to improve outcomes until specific neuroprotective or neurorestorative therapies available.

show abstract

Neuronal Biomarkers in Predicting Neurodevelopmental Outcome in Term Babies with Perinatal Asphyxia

Cited by 16 publications

References 26 publications

Therapeutic hypothermia as a neuroprotective strategy in newborns with perinatal asphyxia—case report

Therapeutic hypothermia as a neuroprotective strategy in newborns with perinatal asphyxia—case report

The contribution of postnatal steroid administration to early brain damage in preterm babies with bronchopulmonary dysplasia

Need for more evidence in the prevention and management of perinatal asphyxia and neonatal encephalopathy in low and middle-income countries: A call for action

Contact Info

Product

Resources

About